CTNM

NASDAQ:CTNM

Contineum Therapeutics

  • Stock

3.97

−3.41%

−2.50

USD last updated 11/08 01:58:28

Last Close

6.47

08/08 20:00

Market Cap

541.73M

Beta: -

Volume Today

132.52K

Avg: -

PE Ratio

−20.64

PFCF: −17.65

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idi...Show More

    Earnings

    Earnings per Share (Estimate*)

    -4-3-2-1122022-12-302023-06-292023-12-302024-08-132024-11-062025-02-262025-05-15

    Revenue (Estimate*)

    10M20M30M40M50M2022-12-302023-06-292023-12-302024-08-132024-11-062025-02-262025-05-15

    *Estimate based on analyst consensus